The study published by the Journal of the American Medical Association brings surprising results
A class of diabetes drugs that includes Ozempic is associated with a reduced risk of some obesity-related cancers, according to a study published this week in the journal American. JAMA (The Journal of the American Medical Association).
The study compared patients with type 2 diabetes treated with insulin to patients who received a class of drugs known as GLP-1 agonists, such as Ozempic, between 2005 and 2018.
The researchers found that patients who received GLP-1 agonists had a significantly lower risk of developing 10 of 13 types of cancer studied, including kidney, pancreatic, esophageal, ovarian, liver, and colorectal cancer.
Among the cancers for which no significant change in risk was found were thyroid cancer and breast cancer in postmenopausal women.
“Obesity is known to be associated with at least 13 types of cancer,” said study author Rong Xu. “Our study provides evidence that GLP-1 agonists have the potential to break the link between obesity and cancer.”
Among the drugs studied were semaglutide — sold commercially as Ozempic — as well as liraglutide and others. GLP-1 agonists have been around for about 20 years, but a new generation of these drugs, including Ozempic, has gained popularity for its more dramatic effects on weight loss.
Xu suggested that the protective benefits demonstrated in the study might encourage doctors to prescribe GLP-1 treatments for diabetes patients instead of other drugs such as insulin.
André Forastieri is a journalist and entrepreneur, founder of Homework and the content and connections agency Compasso, as well as a mentor to professionals and executives. Find out more aboutandreforastieri.com.br
.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
